Cargando…

A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers

ABSTRACT: This Phase I study aimed to assess the potential drug-drug interactions (pharmacokinetic [PK] and safety profile) of Δ9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (Sativex (®), nabiximols) in combination with cytochrome P450 (CYP450) inducer (rifampicin) or inhibitors (k...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stott, Colin, White, Linda, Wright, Stephen, Wilbraham, Darren, Guy, Geoffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing AG 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671111/ https://www.ncbi.nlm.nih.gov/pubmed/23750331 http://dx.doi.org/10.1186/2193-1801-2-236

Ejemplares similares

The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis‐related spasticity
por: Celius, Elisabeth G., et al.
Publicado: (2018)

A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain
por: Überall, Michael A
Publicado: (2020)

The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray)
por: Grimaldi, Alessandro Enrico, et al.
Publicado: (2019)

Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings
por: Flachenecker, Peter, et al.
Publicado: (2018)

An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex(®) (THC:CBD, nabiximols) oromucosal spray
por: Etges, Tilden, et al.
Publicado: (2016)

The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers
por: Liu, Yong, et al.
Publicado: (2014)

A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity
por: Marinelli, Lucio, et al.
Publicado: (2017)

Comparison of the Effectiveness and Tolerability of Nabiximols (THC:CBD) Oromucosal Spray versus Oral Dronabinol (THC) as Add-on Treatment for Severe Neuropathic Pain in Real-World Clinical Practice: Retrospective Analysis of the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2022)

Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects
por: Luedtke, Doreen, et al.
Publicado: (2018)

Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2019)

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
por: Pithavala, Yazdi K., et al.
Publicado: (2010)

Rapid Distinction and Semiquantitative Analysis of THC and CBD by Silver-Impregnated Paper Spray Mass Spectrometry
por: Huang, Si, et al.
Publicado: (2021)

CBD, a precursor of THC in e-cigarettes
por: Czégény, Zsuzsanna, et al.
Publicado: (2021)

Long-Term Consequences of Adolescent Exposure to THC-Rich/CBD-Poor and CBD-Rich/THC-Poor Combinations: A Comparison with Pure THC Treatment in Female Rats
por: Gabaglio, Marina, et al.
Publicado: (2021)

A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆(9)-tetrahydrocannabinol (THC) by vaporisation
por: Solowij, Nadia, et al.
Publicado: (2014)

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
por: Patti, F, et al.
Publicado: (2016)

The Impact of THC and CBD in Schizophrenia: A Systematic Review
por: Ahmed, Saeed, et al.
Publicado: (2021)

Pilot clinical and pharmacokinetic study of Δ(9)-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain
por: Clarke, Stephen, et al.
Publicado: (2022)

Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults
por: Kusawake, Tomohiro, et al.
Publicado: (2017)

THC and CBD: Villain versus Hero? Insights into Adolescent Exposure
por: Pintori, Nicholas, et al.
Publicado: (2023)

Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers
por: Shin, Yesong, et al.
Publicado: (2022)

A Review on Studies of Marijuana for Alzheimer’s Disease – Focusing on CBD, THC
por: Kim, Seok Hee, et al.
Publicado: (2019)

Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?
por: Lachenmeier, Dirk W., et al.
Publicado: (2023)

Potency and Therapeutic THC and CBD Ratios: U.S. Cannabis Markets Overshoot
por: Pennypacker, Sarah D., et al.
Publicado: (2022)

Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers
por: Teng, Renli, et al.
Publicado: (2013)

POTENTIAL BENEFITS OF THC AND CBD IN THE TREATMENT OF HOSPICE-ELIGIBLE DEMENTED AND AGITATED PATIENTS
por: Mintzer, Jacobo`
Publicado: (2022)

Nanomaterials-Based Electrochemical Δ(9)-THC and CBD Sensors for Chronic Pain
por: Pazuki, Dadbeh, et al.
Publicado: (2023)

Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs
por: Chicoine, Alan, et al.
Publicado: (2020)

Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
por: D’hooghe, Marie, et al.
Publicado: (2021)

Pharmacokinetics and bioequivalence evaluation of omeprazole and sodium bicarbonate dry suspensions in healthy Chinese volunteers
por: Zhang, Rui, et al.
Publicado: (2023)

Vape shop owners’/managers’ attitudes about CBD, THC, and marijuana legal markets
por: Berg, Carla J., et al.
Publicado: (2020)

Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC
por: Oultram, Jackson M. J., et al.
Publicado: (2021)

Oromucosal Administration of Interferon to Humans
por: Beilharz, Manfred W., et al.
Publicado: (2010)

Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis
por: Hutten, Nadia R. P. W., et al.
Publicado: (2022)

Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis
por: Stott, K E, et al.
Publicado: (2018)

Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat
por: Becker, Corina, et al.
Publicado: (2013)

Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
por: Narasimhan, Narayana I, et al.
Publicado: (2013)

A prospective open‐label trial of a CBD/THC cannabis oil in dravet syndrome
por: McCoy, Bláthnaid, et al.
Publicado: (2018)

Conversion of Cannabidiol (CBD) into Psychotropic Cannabinoids Including Tetrahydrocannabinol (THC): A Controversy in the Scientific Literature
por: Golombek, Patricia, et al.
Publicado: (2020)

Acute effects of naturalistic THC vs. CBD use on recognition memory: a preliminary study
por: Curran, Tim, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j2ud2idmi0g34tkkgou223ukqa